Based on these observations, our investigation of the properties of circulating CD4+ T cells in patients with active TB led us to suggest that inhibition of KLRG1+ expression through the incorporation of a specific inhibitor of the Akt signaling pathway in a vaccine could enhance the protective responses in immunotherapeutic and perhaps prophylactic vaccination regimens (138). The gene discussed is AKT1; the disease is tuberculosis.